MEDICINOVA INC. - COM

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer

20 May 2024 03:00:00 By Nasdaq GlobeNewswire

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome

14 May 2024 03:00:00 By Nasdaq GlobeNewswire

MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)

07 May 2024 03:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)

02 Apr 2024 16:00:00 By Nasdaq GlobeNewswire

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

26 Mar 2024 16:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society

20 Mar 2024 16:00:00 By Nasdaq GlobeNewswire

MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology

12 Mar 2024 03:30:00 By Nasdaq GlobeNewswire

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

17 Jan 2024 03:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology

21 Dec 2023 15:00:00 By Nasdaq GlobeNewswire

MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

06 Dec 2023 15:00:00 By Nasdaq GlobeNewswire

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

19 Nov 2023 15:00:00 By Nasdaq GlobeNewswire

MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria

26 Oct 2023 22:00:00 By Nasdaq GlobeNewswire

MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada

10 Oct 2023 16:00:00 By Nasdaq GlobeNewswire

MediciNova Receives Gene Therapy Milestone Payment

04 Oct 2023 16:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

27 Sep 2023 16:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology

17 Aug 2023 16:00:00 By Nasdaq GlobeNewswire

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe

16 Aug 2023 16:00:00 By Nasdaq GlobeNewswire

MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe

15 Aug 2023 16:00:00 By Nasdaq GlobeNewswire

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe

14 Aug 2023 16:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting

29 Jun 2023 03:00:00 By Nasdaq GlobeNewswire